Tissue penetration of antimicrobials: Difference between revisions

From IDWiki
mNo edit summary
Β 
(12 intermediate revisions by the same user not shown)
Line 16: Line 16:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 24: Line 24:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |Β±
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 31: Line 31:
|[[piperacillin-tazobactam]]
|[[piperacillin-tazobactam]]
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +†
| style="text-align:center" | +†
| style="text-align:center" |
| style="text-align:center" |
|-
|-
| rowspan="5" |[[Cephalosporins]]
| rowspan="6" |[[Cephalosporins]]
|first-generation cephalosporins
|first-generation cephalosporins
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 49: Line 49:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 57: Line 57:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |Β±
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +†
| style="text-align:center" | +†
| style="text-align:center" |
| style="text-align:center" |
|-
|[[ceftriaxone]]
|
| +
|
|
|
|
|-
|-
|[[cefepime]]
|[[cefepime]]
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 73: Line 81:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |Β±
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 82: Line 90:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 90: Line 98:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
|-
|-
|[[Carbapenems]]
| rowspan="2" |[[Carbapenems]]
|[[imipenem]]
|[[imipenem]]
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
|-
|[[meropenem]]
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 110: Line 126:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 119: Line 135:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
|-
|-
|[[Fluoroquinolones]]
| rowspan="2" |[[Fluoroquinolones]]
|all
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–?
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–?
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" | +
|-
|[[moxifloxacin]]
|
|
|
|–
|
|
|-
|-
|[[Fosfomycin]]
|[[Fosfomycin]]
Line 137: Line 161:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 146: Line 170:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 153: Line 177:
|[[Lipopeptides]]
|[[Lipopeptides]]
|[[daptomycin]]
|[[daptomycin]]
| style="text-align:center" | +
| +
| style="text-align:center" |–
|–
| style="text-align:center" |
|
| style="text-align:center" | +
| +
| style="text-align:center" |
|
| style="text-align:center" |
|
|-
|-
|[[Macrolides]]
|[[Macrolides]]
Line 164: Line 188:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 173: Line 197:
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |–
|
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |–
| style="text-align:center" |–
Line 182: Line 206:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
|-
|[[Oxazolidinones]]
|[[linezolid]]
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |±‑
| style="text-align:center" |
| style="text-align:center" |
|-
|-
|[[Rifamycins]]
|[[Rifamycins]]
Line 191: Line 224:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 200: Line 233:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 209: Line 242:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
Line 217: Line 250:
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |Β±[[CiteRef::jodlowski2020do]]
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" | +
Line 226: Line 259:
|
|
|[[acyclovir]] / [[valacyclovir]]
|[[acyclovir]] / [[valacyclovir]]
| style="text-align:center" |
|
| style="text-align:center" |
|
| style="text-align:center" | +
| +
| style="text-align:center" |
|
| style="text-align:center" |
|
| style="text-align:center" |
|
|-
|-
|
|
|[[ganciclovir]]
|[[ganciclovir]]
| style="text-align:center" |
|
| style="text-align:center" |
|
| style="text-align:center" | +
| +
| style="text-align:center" |
|
| style="text-align:center" |
|
| style="text-align:center" |
|
|-
|-
|
|
|[[foscarnet]]
|[[foscarnet]]
| style="text-align:center" |
|
| style="text-align:center" |
|
| style="text-align:center" |
|
| style="text-align:center" |
|
| style="text-align:center" |
|
| style="text-align:center" |
|
|-
|-
! colspan="8" |Antifungals
! colspan="8" |Antifungals[[CiteRef::felton2014ti]]
|-
|-
|[[Azoles]]
| rowspan="3" |[[Azoles]]
|[[fluconazole]]
|[[fluconazole]]
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |Β±
| style="text-align:center" | +
|-
|[[itraconazole]]
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |Β±
|
| style="text-align:center" |–
| style="text-align:center" | +
| style="text-align:center" |–
| style="text-align:center" |
| style="text-align:center" |
|-
|[[voriconazole]]
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |Β±
| style="text-align:center" |Β±
| style="text-align:center" |Β±
| style="text-align:center" |
| style="text-align:center" |
|-
| rowspan="3" |[[Echinocandins]]
|[[anidulafungin]]
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |Β±
| style="text-align:center" |–
| style="text-align:center" |Β±
| style="text-align:center" |
| style="text-align:center" |
|-
|-
|[[Echinocandins]]
|[[caspofungin]]
| style="text-align:center" | +
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |Β±
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|-
|[[micafungin]]
| style="text-align:center" |
| style="text-align:center" |Β±
| style="text-align:center" |–
| style="text-align:center" |Β±
| style="text-align:center" |
| style="text-align:center" |
|-
| rowspan="2" |[[Polyenes]]
|deoxycholate [[amphotericin B]]
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" | +
| style="text-align:center" | +
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
|
|-
|liposomal [[amphotericin B]]
| style="text-align:center" |
| style="text-align:center" |–
| style="text-align:center" |–
| style="text-align:center" |±†
| style="text-align:center" | +
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
| style="text-align:center" |
Line 275: Line 357:
!Blood
!Blood
!CNS
!CNS
!Vitreous
!
!Urine
!Urine
!Prostate
!Prostate
Line 282: Line 364:


*† if inflammation present
*† if inflammation present
*‑ very low levels, but likely enough for [[Enterococcus]]


==Specific Tissues==
==Specific Tissues==


=== Central Nervous System ===

* Reviewed in [[CiteRef::nau2010pe]]

{| class="wikitable"
!Class
!Antimicrobial
!CSF Penetration (AUC)
!With Meningeal Inflammation
|-
! colspan="4" |Antibiotics
|-
| rowspan="5" |[[penicillins]]
|overall
|2%
|2%
|-
|[[ampicillin]]
|
|
|-
|[[amoxicillin]]
|
|6%
|-
|[[cloxacillin]]
|0.87%
|
|-
|[[piperacillin]]
|3%
|32%
|-
| rowspan="3" |beta lactamase inhibitors
|overall
|7%
|10%
|-
|[[clavulanate]]
|4%
|8%
|-
|[[tazobactam]]
|11%
|
|-
| rowspan="4" |[[cephalosporins]]
|overall
|0.7 to 10%
|15%
|-
|[[cefotaxime]]
|12%
|4 to 17%
|-
|[[ceftriaxone]]
|0.7%
|
|-
|[[ceftazidime]]
|0.6%
|
|-
| rowspan="3" |[[carbapenems]]
|overall
|20%
|30%
|-
|imipenem
|
|14%
|-
|meropenem
|5 to 25%
|39%
|-
|[[aminoglycosides]]
|overall
|20%
|
|-
| rowspan="4" |[[fluoroquinolones]]
|overall
|30 to 70%
|70 to 90%
|-
|[[ciprofloxacin]]
|24 to 43%
|92%
|-
|[[levofloxacin]]
|71%
|
|-
|[[moxifloxacin]]
|46%
|79%
|-
|[[chloramphenicol]]
|
|60 to 70%
|60 to 70%
|-
|[[macrolides]]
|[[clarithromycin]]
|
|18%
|-
|[[tetracyclines]]
|[[doxycycline]]
|20%
|20%
|-
|[[fosfomycin]]
|
|18%
|
|-
|[[linezolid]]
|90%
|
|
|-
|[[metronidazole]]
|
|
|87%
|-
|[[rifamycins]]
|[[rifampin]]
|22%
|
|-
|[[trimethoprim-sulfamethoxazole]]
|[[trimethoprim]]
|18%
|42 to 51%
|-
|
|[[sulfamethoxazole]]
|12%
|24 to 30%
|-
|[[glycopeptides]]
|[[vancomycin]]
|14 to 18%
|30%
|-
|antituberculosis medications
|[[isoniazid]]
|
|86%
|-
! colspan="4" |Antivirls
|-
| rowspan="2" |anti-herpes nucleoside analogues
|[[acyclovir]]
|31%
|
|-
|[[valacyclovir]]
|19%
|
|-
|[[foscarnet]]
|
|27 to 43%
|23 to 66%
|-
| rowspan="4" |HIV antiretrovirals
|[[abacavir]]
|35%
|
|-
|[[zidovudine]]
|75%
|
|-
|[[indinavir]]
|6 to 15%
|
|-
|[[lopinavir]]
|29%
|
|-
! colspan="4" |Antifungals
|-
|
|[[flucytosine]]
|
|74%
|-
| rowspan="2" |[[azoles]]
|[[fluconazole]]
|
|86%
|-
|[[voriconazole]]
|
|46%
|-
|[[polyenes]]
|[[amphotericin B]]
|
|low
|-
! colspan="4" |Antiparasitics
|-
|
|[[albendazole]]
|38 to 43%
|
|-
|
|[[praziquantel]]
|24%
|
|-
|
|[[sulfadiazine]]
|27 to 33%
|
|}
===Prostate===
===Prostate===


Line 318: Line 625:
! colspan="5" |Antibiotics
! colspan="5" |Antibiotics
|-
|-
| rowspan="3" |penicillins
| rowspan="3" |[[penicillins]]
|[[ampicillin]]
|[[ampicillin]]
|
|
Line 334: Line 641:
|[[CiteRef::brockhaus2019re]]
|[[CiteRef::brockhaus2019re]]
|-
|-
| rowspan="4" |cephalosporins
| rowspan="4" |[[cephalosporins]]
|[[cefazolin]]
|[[cefazolin]]
|
|
Line 355: Line 662:
|[[CiteRef::brockhaus2019re]]
|[[CiteRef::brockhaus2019re]]
|-
|-
| rowspan="2" |carbapenems
| rowspan="2" |[[carbapenems]]
|[[imipenem]]
|[[imipenem]]
|
|
Line 366: Line 673:
|[[CiteRef::brockhaus2019re]]
|[[CiteRef::brockhaus2019re]]
|-
|-
|oxazolidinones
|[[oxazolidinones]]
|[[linezolid]]
|[[linezolid]]
|
|
Line 384: Line 691:
|[[CiteRef::brockhaus2019re]]
|[[CiteRef::brockhaus2019re]]
|-
|-
| rowspan="2" |aminoglycosides
| rowspan="2" |[[aminoglycosides]]
|[[amikacin]]
|[[amikacin]]
|
|
Line 395: Line 702:
|[[CiteRef::brockhaus2019re]]
|[[CiteRef::brockhaus2019re]]
|-
|-
| rowspan="3" |fluoroquinolones
| rowspan="3" |[[fluoroquinolones]]
|[[ciprofloxacin]]
|[[ciprofloxacin]]
|
|
Line 413: Line 720:
! colspan="5" |Antifungals
! colspan="5" |Antifungals
|-
|-
| rowspan="4" |azoles
| rowspan="4" |[[azoles]]
|[[fluconazole]]
|[[fluconazole]]
|40 to 50%
|40 to 50%
Line 440: Line 747:
|[[CiteRef::felton2014ti]]
|[[CiteRef::felton2014ti]]
|-
|-
|[[polyenes]]
|
|liposomal amphotericin B
|liposomal amphotericin B
|
|
Line 446: Line 753:
|[[CiteRef::felton2014ti]]
|[[CiteRef::felton2014ti]]
|-
|-
| rowspan="2" |echinocandins
| rowspan="2" |[[echinocandins]]
|echinocandins
|echinocandins
|
|
Line 456: Line 763:
|undetectable
|undetectable
|[[CiteRef::suzuki2008oc]][[CiteRef::felton2014ti]]
|[[CiteRef::suzuki2008oc]][[CiteRef::felton2014ti]]
|-
! colspan="5" |Antivirals
|-
|
|[[acyclovir]]
|
|above IC
|
|-
|
|[[valacyclovir]]
|
|20 to 30%, above IC in non-inflamed human eyes
|[[CiteRef::huynh2008vi]]
|-
|
|[[ganciclovir]]
|
|close to IC
|
|-
|
|[[foscarnet]]
|100%
|10%, close to IC
|[[CiteRef::lΓ³pez-cortΓ©s2000in]]
|}
|}
[[Category:Antimicrobials]]
[[Category:Antimicrobials]]

Latest revision as of 17:51, 19 September 2024

Summary

Class Antimicrobial Blood CNS Vitreous Urine Prostate Necrotic
Antibiotics: Ξ²-Lactams
Penicillins Ξ²-lactamase inhibitors –
ampicillin + Β± –
piperacillin-tazobactam – – +†
Cephalosporins first-generation cephalosporins – – –
second-generation cephalosporins –
third-generation cephalosporins Β± +†
ceftriaxone +
cefepime +
ceftazidime + Β± +
Cephamycins cephamycins –
cefoxitin –
Carbapenems imipenem +
meropenem + + +
Antibiotics: Non-Ξ²-Lactams
Aminoglycosides –
Chloramphenicol chloramphenicol +
Fluoroquinolones all –? + +
moxifloxacin –
Fosfomycin fosfomycin +
Lincosamides clindamycin – +
Lipopeptides daptomycin + – +
Macrolides macrolides – +
Nitrofurans nitrofurantoin – – – + – –
Nitroimidazoles metronidazole +
Oxazolidinones linezolid + + + ±‑
Rifamycins rifampin +
Sulfonamides trimethoprim-sulfamethoxazole +
Tetracyclines tetracyclines – +
doxycycline Β±1 + +
Antivirals
acyclovir / valacyclovir +
ganciclovir +
foscarnet
Antifungals2
Azoles fluconazole + + + Β± +
itraconazole Β± – + –
voriconazole Β± Β± Β±
Echinocandins anidulafungin + Β± – Β±
caspofungin + – – Β±
micafungin Β± – Β±
Polyenes deoxycholate amphotericin B – +
liposomal amphotericin B – ±† +
Class Antimicrobial Blood CNS Vitreous Urine Prostate Necrotic
  • † if inflammation present
  • ‑ very low levels, but likely enough for Enterococcus

Specific Tissues

Central Nervous System

  • Reviewed in 3
Class Antimicrobial CSF Penetration (AUC) With Meningeal Inflammation
Antibiotics
penicillins overall 2% 2%
ampicillin
amoxicillin 6%
cloxacillin 0.87%
piperacillin 3% 32%
beta lactamase inhibitors overall 7% 10%
clavulanate 4% 8%
tazobactam 11%
cephalosporins overall 0.7 to 10% 15%
cefotaxime 12% 4 to 17%
ceftriaxone 0.7%
ceftazidime 0.6%
carbapenems overall 20% 30%
imipenem 14%
meropenem 5 to 25% 39%
aminoglycosides overall 20%
fluoroquinolones overall 30 to 70% 70 to 90%
ciprofloxacin 24 to 43% 92%
levofloxacin 71%
moxifloxacin 46% 79%
chloramphenicol 60 to 70% 60 to 70%
macrolides clarithromycin 18%
tetracyclines doxycycline 20% 20%
fosfomycin 18%
linezolid 90%
metronidazole 87%
rifamycins rifampin 22%
trimethoprim-sulfamethoxazole trimethoprim 18% 42 to 51%
sulfamethoxazole 12% 24 to 30%
glycopeptides vancomycin 14 to 18% 30%
antituberculosis medications isoniazid 86%
Antivirls
anti-herpes nucleoside analogues acyclovir 31%
valacyclovir 19%
foscarnet 27 to 43% 23 to 66%
HIV antiretrovirals abacavir 35%
zidovudine 75%
indinavir 6 to 15%
lopinavir 29%
Antifungals
flucytosine 74%
azoles fluconazole 86%
voriconazole 46%
polyenes amphotericin B low
Antiparasitics
albendazole 38 to 43%
praziquantel 24%
sulfadiazine 27 to 33%

Prostate

  • Poorly penetrated by most antibiotics
  • Penetration is higher with a high concentration gradient, high lipid solubility, low degree of ionization, high dissociation constant, low protein binding, and small molecular size
  • Fluoroquinolones are the mainstay of therapy, though there is increasing resistance
  • TMP-SMX often used, though conflicting data about its penetration into the prostate
  • Minocycline, doxycycline, and macrolides achieve high levels in the prostate but are rarely indicated for the causative organisms
  • Third-generation cephalosporins and carbapenems can be used
  • Piperacillin, aztreonam, imipenem, and some aminoglycosides are likely useful

Bone

  • Essentially all antibiotics achieve similar bone-to-serum levels, with the exception of oral Ξ²-lactams which nevertheless have no worse outcomes4

Eye

Class Antimicrobial Retinal Penetration Vitreal Penetration Ref
Antibiotics
penicillins ampicillin below MIC in non-inflamed rabbit eyes 5
amoxicillin 2% (below MIC) in non-inflamed rabbit eyes 5
piperacillin undetectable in inflamed human eyes 5
cephalosporins cefazolin above MIC in inflamed rabbit eyes 5
ceftriaxone 4% in non-inflamed human eyes 5
ceftazidime 30% in inflamed rabbit eyes 5
cefipime 8% in non-inflamed human eyes 5
carbapenems imipenem 8 to 10% in non-inflamed human eyes 5
meropenem 30% in non-inflamed human eyes 5
oxazolidinones linezolid 30 to 80% in non-inflamed human eyes 5
vancomycin above MIC in inflamed rabbit eyes 5
daptomycin 30% in inflamed human eyes 5
aminoglycosides amikacin below MIC in inflamed rabbit eyes 5
gentamicin below MIC in inflamed rabbit eyes 5
fluoroquinolones ciprofloxacin below MIC in non-inflamed human eyes 5
levofloxacin 30% but below MIC in non-inflamed human eyes 5
moxifloxacin 10 to 40% and above MIC in non-inflamed human eyes 5
Antifungals
azoles fluconazole 40 to 50% 40 to 50% 62
itraconazole 10% in inflamed eyes 2
posaconazole 20% in inflamed eyes 2
voriconazole 40 to 100% 2
flucytosine 40 to 100% 2
polyenes liposomal amphotericin B only detectable in inflamed eyes 2
echinocandins echinocandins very low penetration 2
micafungin excellent undetectable 62
Antivirals
acyclovir above IC
valacyclovir 20 to 30%, above IC in non-inflamed human eyes 7
ganciclovir close to IC
foscarnet 100% 10%, close to IC 8

References

  1. ^  Cornelia B. Landersdorfer, JΓΌrgen B. Bulitta, Martina Kinzig, Ulrike Holzgrabe, Fritz SΓΆrgel. Penetration of Antibacterials into Bone. Clinical Pharmacokinetics. 2009;48(2):89-124. doi:10.2165/00003088-200948020-00002.